Dongsung Pharmaceutical delayed disclosure of embezzlement and breach of trust suspicion by approximately one year, reporting it on June 23, 2026, after the incident occurred on June 27, 2025. Consequently, the Securities Market Division issued a notice of designation as an untimely disclosure corporation.
The company has accumulated 14.5 penalty points over the past year. Additional points from this case may trigger a substantive review for listing eligibility, increasing the risk of delisting.
This disclosure does not include any shareholder return policies such as treasury stock acquisitions or dividends.
[AI Summary]The untimely disclosure indicates weak internal controls and governance failures. With cumulative penalty points of 14.5 and potential additional points, the stock price and investor confidence are likely to suffer. The delisting risk poses a serious threat to shareholder value, requiring investor caution.
KOSPI Filing Information
Advance Notice of Designation as Unfaithful Disclosure Corporation